Pierre Miossec Selected Research

Interleukin-17 (Interleukin 17)

2/2022	Gastroenterological safety of IL-17 inhibitors: a systematic literature review.
1/2022	The Th17 Pathway in Vascular Inflammation: Culprit or Consort?
1/2021	Local and systemic effects of IL-17 in joint inflammation: a historical perspective from discovery to targeting.
1/2020	Synergistic Interaction Between High Bioactive IL-17A and Joint Destruction for the Occurrence of Cardiovascular Events in Rheumatoid Arthritis.
12/2019	The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis.
1/2019	Additive or Synergistic Interactions Between IL-17A or IL-17F and TNF or IL-1β Depend on the Cell Type.
1/2019	Systemic effects of IL-17 in inflammatory arthritis.
12/2018	IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases.
1/2018	Differential effects of TNF-α and IL-1β on the control of metal metabolism and cadmium-induced cell death in chronic inflammation.
1/2018	IL-17 in Rheumatoid Arthritis and Precision Medicine: From Synovitis Expression to Circulating Bioactive Levels.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pierre Miossec Research Topics

Disease

70	Rheumatoid Arthritis 01/2022 - 03/2003
39	Inflammation (Inflammations) 01/2022 - 03/2003
15	Arthritis (Polyarthritis) 01/2021 - 10/2002
12	Necrosis 01/2018 - 03/2003
8	Psoriasis (Pustulosis Palmaris et Plantaris) 02/2022 - 04/2009
6	Psoriatic Arthritis 02/2022 - 03/2016
6	Myositis (Idiopathic Inflammatory Myopathies) 01/2018 - 08/2007
5	Ankylosing Spondylitis 02/2022 - 03/2016
5	Vasculitis (Vasculitides) 01/2022 - 05/2018
5	Infections 01/2020 - 10/2002
5	Osteoarthritis 11/2019 - 03/2009
4	Dermatomyositis (Dermatopolymyositis) 01/2022 - 01/2004
4	Thrombosis (Thrombus) 01/2022 - 09/2017
3	Multiple Sclerosis 01/2022 - 04/2009
3	Hyperplasia 01/2022 - 10/2010
3	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 12/2009
3	Rheumatic Diseases (Rheumatism) 02/2016 - 01/2009
3	Polymyositis 06/2009 - 01/2004
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 02/2022 - 07/2012
2	Myocardial Infarction 01/2020 - 01/2017
2	Joint Diseases (Joint Disease) 05/2019 - 01/2014
2	Synovitis 01/2018 - 01/2008
2	Hepatitis 05/2017 - 02/2008
2	Mycoses (Diseases, Fungus) 01/2017 - 03/2016
2	Neoplasms (Cancer) 10/2016 - 06/2007
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 07/2012 - 01/2011
2	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 08/2011 - 07/2007
2	Tertiary Lymphoid Structures 09/2004 - 05/2002
1	Giant Cell Arteritis (Horton Disease) 01/2022
1	Pigmented Villonodular Synovitis 01/2022
1	Hypertrophy 01/2022
1	Granuloma 01/2021
1	Glomerulonephritis 01/2021
1	Latent Tuberculosis 01/2021
1	COVID-19 12/2020
1	Cytokine Release Syndrome 12/2020
1	Neurologic Manifestations (Neurological Manifestations) 11/2020
1	Hepatitis C 01/2020
1	Sacroiliitis 12/2019
1	Axial Spondyloarthritis 12/2019
1	Obesity 11/2019
1	Periodontal Diseases (Periodontal Disease) 05/2019
1	Bone Resorption 01/2019

Drug/Important Bio-Agent (IBA)

49	Interleukin-17 (Interleukin 17)IBA 02/2022 - 03/2003
37	CytokinesIBA 01/2022 - 03/2003
19	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 01/2004
8	InterleukinsIBA 01/2021 - 02/2007
6	Infliximab (Remicade)FDA Link 05/2019 - 01/2005
6	Interleukin-1 (Interleukin 1)IBA 08/2007 - 03/2003
5	ChemokinesIBA 01/2021 - 05/2002
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 06/2009
5	Methotrexate (Mexate)FDA LinkGeneric 01/2019 - 04/2005
5	Interleukin-6 (Interleukin 6)IBA 01/2017 - 05/2007
4	CadmiumIBA 01/2022 - 01/2017
4	EnzymesIBA 01/2019 - 02/2007
4	Pharmaceutical PreparationsIBA 01/2019 - 10/2002
4	ZincIBA 01/2017 - 04/2015
4	Messenger RNA (mRNA)IBA 08/2012 - 06/2004
3	CryoglobulinsIBA 01/2022 - 05/2018
3	Tumor Necrosis Factor InhibitorsIBA 01/2021 - 07/2007
3	Interleukin-12 (IL 12)IBA 01/2021 - 01/2004
3	Biological ProductsIBA 01/2021 - 02/2011
3	Immunoglobulin G (IgG)IBA 11/2020 - 07/2015
3	Antigen-Antibody Complex (Immune Complex)IBA 05/2018 - 07/2015
3	Interferon Type IIBA 07/2013 - 01/2011
3	EpitopesIBA 01/2010 - 02/2007
3	Interleukin-18 (Interleukin 18)IBA 05/2004 - 03/2003
2	Interferon-gamma (Interferon, gamma)IBA 01/2022 - 06/2009
2	Monoclonal AntibodiesIBA 01/2022 - 12/2019
2	SteroidsIBA 01/2022 - 01/2016
2	InterferonsIBA 01/2021 - 02/2012
2	Immunoglobulins (Immunoglobulin)IBA 01/2020 - 06/2009
2	Interleukin-23 (Interleukin 23)IBA 12/2019 - 05/2007
2	Biomarkers (Surrogate Marker)IBA 05/2019 - 07/2010
2	Rheumatoid FactorIBA 07/2015 - 07/2007
2	Toll-Like Receptors (Toll-Like Receptor)IBA 07/2013 - 02/2012
2	DNA (Deoxyribonucleic Acid)IBA 08/2012 - 12/2007
2	Etanercept (Enbrel)FDA Link 08/2012 - 04/2005
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 10/2010 - 07/2006
2	HLA-DR Antigens (HLA-DR)IBA 01/2010 - 12/2007
2	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 05/2004 - 01/2004
2	NF-kappa B (NF-kB)IBA 05/2004 - 01/2004
1	HemosiderinIBA 01/2022
1	Interleukin-6 InhibitorsIBA 01/2022
1	Interleukin-12 Receptors (Interleukin 12 Receptor)IBA 01/2021
1	AnionsIBA 01/2021
1	FatsIBA 11/2019
1	SugarsIBA 11/2019
1	C-Reactive ProteinIBA 05/2019
1	Matrix Metalloproteinase 3 (Stromelysin 1)IBA 05/2019
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2019
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2019
1	Cathepsin KIBA 01/2019
1	Prealbumin (Transthyretin)IBA 01/2019
1	Tartrate-Resistant Acid PhosphataseIBA 01/2019
1	S100A12 ProteinIBA 01/2019
1	Platelet Factor 4IBA 01/2019

Therapy/Procedure

9	Therapeutics 01/2021 - 05/2007
2	Biological Therapy 01/2019 - 01/2016
2	Intra-Articular Injections 01/2017 - 01/2017